Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

IONS Ionis Pharmaceuticals, Inc. Common Stock
$44.84 -5.10% -2.41
Notify me if price changes either direction
Interactive Brokers Logotype

Buy IONS stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 7.5B
Enterprise value 8.6B
Trailing PE -18.844537174
Forward PE -46.246513
PEG Ratio 0.099991421739594
Enterprise to EBITDA -14.901
Enterprise to revenue 9.879
Price to book MRQ 19.374763
Price to sales TTM 9.779876

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 874.1M
EBITDA -579484992
Diluted EPS TTM -3.48
Total Cash (MRQ) 2.1B
Current ratio (MRQ) 7.893
Operating Cash Flow (TTM) -496433984

IONS trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent IONS News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.